Treatment of shock using adrenomedullin and adrenomedullin binding protein-1
View Patent ↗The present invention provides methods of preventing organ destruction and shut-down due to shock in a patient suffering from sepsis or at risk for sepsis, comprising administering adrenomedullin and adrenomedullin binding protein-1 to the patient. Also provided are compositions containing adrenomedullin and adrenomedullin binding protein-1 or precursors, in a pharmaceutically acceptable carrier.
1. A method of attenuating organ damage due to shock in a patient who is suffering sepsis or is likely to suffer sepsis, the method comprising administering to the patient amounts of adrenomedullin and adrenomedullin binding protein-1 effective to attenuate organ damage in the patient.
2. The method of claim 1 wherein the adrenomedullin and adrenomedullin binding protein-1 are administered as one single composition.
3. The method of claim 2 wherein said composition is administered before onset of sepsis.
4. The method of claim 2 wherein the composition is administered during the hyperdynamic phase of sepsis.
5. A composition comprising, adrenomedullin and adrenomedullin binding protein-1 in amounts effective to prevent organ damage in a patient due to shock.
6. The method of claim 1 , wherein the adrenomedullin or the adrenomedullin binding protein-1, or both, further comprises a protective group that is deprotected after administration to the patient.
7. The method of claim 6 , wherein the protective group is an amide or ester group.
8. The composition of claim 5 , wherein the adrenomedullin or the adrenomedullin binding protein-1, or both, further comprises a protective group that is deprotected when the composition is administered to a patient.
9. The composition of claim 8 , wherein the protective group is an amide or ester group.